[go: up one dir, main page]

ES2195785A1 - Nuevos derivados de piridazin-3(2h)-ona. - Google Patents

Nuevos derivados de piridazin-3(2h)-ona.

Info

Publication number
ES2195785A1
ES2195785A1 ES200201111A ES200201111A ES2195785A1 ES 2195785 A1 ES2195785 A1 ES 2195785A1 ES 200201111 A ES200201111 A ES 200201111A ES 200201111 A ES200201111 A ES 200201111A ES 2195785 A1 ES2195785 A1 ES 2195785A1
Authority
ES
Spain
Prior art keywords
derivatives
pyridazin
pde4 inhibitors
inhibitors
phosphodiesterase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES200201111A
Other languages
English (en)
Other versions
ES2195785B1 (es
Inventor
Piaz Vittorio Dal
Maria Paola Giovannoni
Claudia Vergelli
Izquierdo Nuria Aguilar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Almirall SA
Original Assignee
Almirall Prodesfarma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES200201111A priority Critical patent/ES2195785B1/es
Application filed by Almirall Prodesfarma SA filed Critical Almirall Prodesfarma SA
Priority to EP03735387A priority patent/EP1503992A1/en
Priority to KR10-2004-7018292A priority patent/KR20040106536A/ko
Priority to RU2004136977/04A priority patent/RU2326869C2/ru
Priority to PCT/EP2003/005056 priority patent/WO2003097613A1/en
Priority to US10/513,219 priority patent/US7459453B2/en
Priority to NZ536604A priority patent/NZ536604A/en
Priority to UY27807A priority patent/UY27807A1/es
Priority to CNB03816342XA priority patent/CN1324014C/zh
Priority to PE2003000462A priority patent/PE20040689A1/es
Priority to UA20041210293A priority patent/UA77532C2/uk
Priority to JP2004505346A priority patent/JP2005533024A/ja
Priority to AU2003236648A priority patent/AU2003236648A1/en
Priority to BR0310106-1A priority patent/BR0310106A/pt
Priority to CA002485896A priority patent/CA2485896A1/en
Priority to MXPA04011209A priority patent/MXPA04011209A/es
Priority to ARP030101684A priority patent/AR040076A1/es
Priority to MYPI20031820A priority patent/MY132106A/en
Priority to TW092113343A priority patent/TWI309981B/zh
Publication of ES2195785A1 publication Critical patent/ES2195785A1/es
Priority to EC2004005410A priority patent/ECSP045410A/es
Priority to ZA200409173A priority patent/ZA200409173B/en
Priority to IL16517304A priority patent/IL165173A0/xx
Priority to NO20045461A priority patent/NO20045461L/no
Application granted granted Critical
Publication of ES2195785B1 publication Critical patent/ES2195785B1/es
Priority to US12/141,712 priority patent/US20080269235A1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22—Nitrogen and oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Nuevos derivados de pirideazin-3(2H)-ona que tiene la estructura química de fórmula general (I) **FIGURA** así como procedimientos para su preparación, composiciones farmacéuticas que los contienen y su uso en terapia como inhibidores de fosfodiesterasa 4.
ES200201111A 2002-05-16 2002-05-16 Nuevos derivados de piridazin-3(2h)-ona. Expired - Fee Related ES2195785B1 (es)

Priority Applications (24)

Application Number Priority Date Filing Date Title
ES200201111A ES2195785B1 (es) 2002-05-16 2002-05-16 Nuevos derivados de piridazin-3(2h)-ona.
BR0310106-1A BR0310106A (pt) 2002-05-16 2003-05-14 Composto, processo para a produção de um composto, composição farmacêutica, uso do composto e método para o tratamento de um sujeito em sofrimento de uma condição ou doença patalógica
RU2004136977/04A RU2326869C2 (ru) 2002-05-16 2003-05-14 Производные пиридазин-3(2h)-она в качестве ингибиторов фосфодиэстеразы 4 (pde4), способ их получения, фармацевтическая композиция и способ лечения
PCT/EP2003/005056 WO2003097613A1 (en) 2002-05-16 2003-05-14 Pyridazin-3(2h)-one derivatives as pde4 inhibitors
MXPA04011209A MXPA04011209A (es) 2002-05-16 2003-05-14 Derivados de piridazin-3(2h)-ona como inhibidores de pde4.
NZ536604A NZ536604A (en) 2002-05-16 2003-05-14 Pyridazin-3(2H)-one derivatives as PDE4 inhibitors
UY27807A UY27807A1 (es) 2002-05-16 2003-05-14 Nuevos derivados de piridazin-3(2h)-ona
CNB03816342XA CN1324014C (zh) 2002-05-16 2003-05-14 用作pde4抑制剂的哒嗪－3(2h)－酮衍生物、制备方法以及其组合物和用途
PE2003000462A PE20040689A1 (es) 2002-05-16 2003-05-14 Nuevos derivados de piridazin-3(2h)-ona
KR10-2004-7018292A KR20040106536A (ko) 2002-05-16 2003-05-14 Ｐｄｅ４ 저해제로서의 피리다진-３(２ｈ)-온 유도체
JP2004505346A JP2005533024A (ja) 2002-05-16 2003-05-14 Ｐｄｅ４阻害剤としてのピリダジン−３（２ｈ）−オン誘導体
AU2003236648A AU2003236648A1 (en) 2002-05-16 2003-05-14 Pyridazin-3(2h)-one derivatives as pde4 inhibitors
EP03735387A EP1503992A1 (en) 2002-05-16 2003-05-14 Pyridazin-3(2h)-one derivatives as pde4 inhibitors
UA20041210293A UA77532C2 (en) 2002-05-16 2003-05-14 Pyridazin-3(2h)-one derivatives as phosphodiesterase 4 inhibitors
US10/513,219 US7459453B2 (en) 2002-05-16 2003-05-14 Pyridazin-3(2H)-one derivatives as PDE4 inhibitors
CA002485896A CA2485896A1 (en) 2002-05-16 2003-05-14 Pyridazin-3(2h)-one derivatives as pde4 inhibitors
ARP030101684A AR040076A1 (es) 2002-05-16 2003-05-15 Derivados de piridazin-3(2h)-ona
MYPI20031820A MY132106A (en) 2002-05-16 2003-05-16 New pyridazin-3(2h)-one derivatives
TW092113343A TWI309981B (en) 2002-05-16 2003-05-16 New pyridazin-3(2h)-one derivatives
EC2004005410A ECSP045410A (es) 2002-05-16 2004-11-05 Nuevos derivados de piridazin-3(2h)-ona
ZA200409173A ZA200409173B (en) 2002-05-16 2004-11-11 Pyridazin-3(2H)-one derivatives as PDE4 inhibitors.
IL16517304A IL165173A0 (en) 2002-05-16 2004-11-11 Pyridazin-3(2H)-one derivatives as pde4 inhibitors
NO20045461A NO20045461L (no) 2002-05-16 2004-12-15 Nye pyridazin 3-(2H)-on derivater som PDE4-inhibitorer
US12/141,712 US20080269235A1 (en) 2002-05-16 2008-06-18 Pyridazin-3 (2h) -one derivatives as pde4 inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200201111A ES2195785B1 (es) 2002-05-16 2002-05-16 Nuevos derivados de piridazin-3(2h)-ona.

Publications (2)

Publication Number Publication Date
ES2195785A1 true ES2195785A1 (es) 2003-12-01
ES2195785B1 ES2195785B1 (es) 2005-03-16

Family

ID=29433276

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200201111A Expired - Fee Related ES2195785B1 (es) 2002-05-16 2002-05-16 Nuevos derivados de piridazin-3(2h)-ona.

Country Status (23)

Country Link
US (2) US7459453B2 (es)
EP (1) EP1503992A1 (es)
JP (1) JP2005533024A (es)
KR (1) KR20040106536A (es)
CN (1) CN1324014C (es)
AR (1) AR040076A1 (es)
AU (1) AU2003236648A1 (es)
BR (1) BR0310106A (es)
CA (1) CA2485896A1 (es)
EC (1) ECSP045410A (es)
ES (1) ES2195785B1 (es)
IL (1) IL165173A0 (es)
MX (1) MXPA04011209A (es)
MY (1) MY132106A (es)
NO (1) NO20045461L (es)
NZ (1) NZ536604A (es)
PE (1) PE20040689A1 (es)
RU (1) RU2326869C2 (es)
TW (1) TWI309981B (es)
UA (1) UA77532C2 (es)
UY (1) UY27807A1 (es)
WO (1) WO2003097613A1 (es)
ZA (1) ZA200409173B (es)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2251867A1 (es) * 2004-06-21 2006-05-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2251866A1 (es) * 2004-06-18 2006-05-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214687B2 (en) 1999-07-14 2007-05-08 Almirall Ag Quinuclidine derivatives and medicinal compositions containing the same
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
ES2211344B1 (es) * 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
CN1938296A (zh) * 2004-04-01 2007-03-28 安斯泰来制药有限公司 作为腺苷拮抗剂的吡嗪衍生物及其制药用途
CA2562315A1 (en) * 2004-05-19 2005-12-01 Basf Aktiengesellschaft 2-substituted pyrimidines and their use as pesticides
ES2257152B1 (es) 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
SI1765404T1 (sl) 2004-05-31 2009-04-30 Almirall Lab Kombinacije, ki obsegajo antimuskarinska sredstva in beta-adrenergične agoniste
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2298049B1 (es) 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
JP2010519204A (ja) * 2007-02-16 2010-06-03 アムジエン・インコーポレーテツド 窒素含有複素環ケトン類およびそれらのｃ−Ｍｅｔ阻害薬としての使用
ES2320954B1 (es) * 2007-03-02 2010-03-16 Laboratorio Almirall S.A. Nuevo procedimiento de preparacion de 3-metil-4-fenilisoxazolo (3,4-d)iridazin-7(6h)-ona.
ES2320955B1 (es) 2007-03-02 2010-03-16 Laboratorios Almirall S.A. Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
EP2096105A1 (en) 2008-02-28 2009-09-02 Laboratorios Almirall, S.A. Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2108641A1 (en) 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
EP2113503A1 (en) 2008-04-28 2009-11-04 Laboratorios Almirall, S.A. New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
EP2196465A1 (en) 2008-12-15 2010-06-16 Almirall, S.A. (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
UY32297A (es) 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
EP2221055A1 (en) 2009-02-18 2010-08-25 Almirall, S.A. 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one for the treatment of lung function
EP2221297A1 (en) 2009-02-18 2010-08-25 Almirall, S.A. 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one and its use in the treatment of pulmonary diseases
EP2226323A1 (en) 2009-02-27 2010-09-08 Almirall, S.A. New tetrahydropyrazolo[3,4-c]isoquinolin-5-amine derivatives
EP2228368A1 (en) 2009-03-12 2010-09-15 Almirall, S.A. Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
EP2322176A1 (en) 2009-11-11 2011-05-18 Almirall, S.A. New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives
EP2338888A1 (en) 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridine derivatives as JAK inhibitors
UY33213A (es) 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
EP2360158A1 (en) 2010-02-18 2011-08-24 Almirall, S.A. Pyrazole derivatives as jak inhibitors
EP2380890A1 (en) 2010-04-23 2011-10-26 Almirall, S.A. New 7,8-dihydro-1,6-naphthyridin-5(6h)-one-derivatives as PDE4 inhibitors
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
EP2394998A1 (en) 2010-05-31 2011-12-14 Almirall, S.A. 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors
EP2397482A1 (en) 2010-06-15 2011-12-21 Almirall, S.A. Heteroaryl imidazolone derivatives as jak inhibitors
EP2441755A1 (en) 2010-09-30 2012-04-18 Almirall, S.A. Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
EP2489663A1 (en) 2011-02-16 2012-08-22 Almirall, S.A. Compounds as syk kinase inhibitors
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
EP2518071A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Imidazopyridine derivatives as PI3K inhibitors
EP2518070A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
EP2526945A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. New CRTH2 Antagonists
EP2548876A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists
EP2548863A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists.
EP2554544A1 (en) 2011-08-01 2013-02-06 Almirall, S.A. Pyridin-2(1h)-one derivatives as jak inhibitors
EP2578570A1 (en) 2011-10-07 2013-04-10 Almirall, S.A. Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
EP2592077A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
EP2647627A1 (en) 2012-04-02 2013-10-09 Almirall, S.A. Salts of 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phenylethoxy)phenyl] ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1h)-one.
EP2666465A1 (en) 2012-05-25 2013-11-27 Almirall, S.A. Novel dosage and formulation
EP2668941A1 (en) 2012-05-31 2013-12-04 Almirall, S.A. Novel dosage form and formulation of abediterol
BR112014031068A2 (pt) 2012-06-12 2017-06-27 Abbvie Inc derivados piridinona e piridazinona
WO2014060431A1 (en) 2012-10-16 2014-04-24 Almirall, S.A. Pyrrolotriazinone derivatives as pi3k inhibitors
EP2738172A1 (en) 2012-11-28 2014-06-04 Almirall, S.A. New bicyclic compounds as crac channel modulators
DK2931275T3 (da) 2012-12-17 2022-07-04 Almirall Sa Aclidinium til anvendelse i øgning af fysisk aktivitet i hverdagen hos en patient, der lider af kronisk, obstruktiv lungesygdom
ES2750523T3 (es) 2012-12-18 2020-03-26 Almirall Sa Derivados de ciclohexil y quinuclidinil carbamato que tienen actividades de agonista beta2 adrenérgicos y antagonistas muscarínicos M3
AR094797A1 (es) 2013-02-15 2015-08-26 Almirall Sa Derivados de pirrolotriazina como inhibidores de pi3k
EP2848615A1 (en) 2013-07-03 2015-03-18 Almirall, S.A. New pyrazole derivatives as CRAC channel modulators
HUE048371T2 (hu) 2013-10-18 2020-07-28 Celgene Quanticel Res Inc Bromodomén inhibitorok
TW202304907A (zh) 2016-04-15 2023-02-01 美商艾伯維有限公司 溴域抑制劑

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA927755B (en) 1991-10-09 1994-04-08 Syntex Inc Pyrido pyridazinone and pyridazinthione compounds
AU1466395A (en) * 1994-01-25 1995-08-08 Nissan Chemical Industries Ltd. Pyridazinone derivative
DE19533975A1 (de) 1995-09-14 1997-03-20 Merck Patent Gmbh Arylalkyl-diazinone
JP2000510865A (ja) 1996-05-20 2000-08-22 ダーウィン・ディスカバリー・リミテッド Ｔｎｆとｐｄｅ―ｉｖのインヒビターとしてのキノリンカルボキサミド
HUP0100042A3 (en) 1996-05-20 2003-01-28 Darwin Discovery Ltd Cambridge Benzofuran carboxamides medicaments containing the same and their therapeutic use
JP2001523712A (ja) 1997-11-25 2001-11-27 ワーナー−ランバート・カンパニー Ｐｄｅ−ｉｖのベンゼンスルホンアミド阻害剤およびそれらの治療的使用
WO2000050402A1 (en) 1999-02-25 2000-08-31 Merck Frosst Canada & Co. Pde iv inhibiting compounds, compositions and methods of treatment
PL358057A1 (en) * 2000-06-05 2004-08-09 Altana Pharma Ag Compounds effective as beta-2-adrenoreceptor agonists as well as pde4-inhibitors
US6699890B2 (en) 2000-12-22 2004-03-02 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CICIANI, C. et al.: Synthesis and evaluation of in vitro antitumor activity of some substituted 5-pyridazinyl-styrylketones. Il Farmaco, 1991, Vol. 46, nö (7,8), Páginas 873-885. Tabla I. *
DAL PIAZ et al.: "5-acyl-6-aryl 4 nitro-3(2H)pyridazinones and related 4-amino compounds: Synthesis and pharmacological evaluation". J. of Pharm. Sciences, 1991, Vol. 80, nö 4, páginas 341-348. Tabla III. *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2251866A1 (es) * 2004-06-18 2006-05-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2251867A1 (es) * 2004-06-21 2006-05-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.

Also Published As

Publication number Publication date
TWI309981B (en) 2009-05-21
AU2003236648A1 (en) 2003-12-02
TW200400033A (en) 2004-01-01
ES2195785B1 (es) 2005-03-16
US7459453B2 (en) 2008-12-02
WO2003097613A1 (en) 2003-11-27
CN1668603A (zh) 2005-09-14
US20080269235A1 (en) 2008-10-30
NZ536604A (en) 2006-07-28
RU2004136977A (ru) 2005-07-10
CN1324014C (zh) 2007-07-04
US20060052379A1 (en) 2006-03-09
ZA200409173B (en) 2005-07-29
UY27807A1 (es) 2003-11-28
NO20045461L (no) 2005-01-19
MY132106A (en) 2007-09-28
KR20040106536A (ko) 2004-12-17
AR040076A1 (es) 2005-03-16
BR0310106A (pt) 2005-02-22
EP1503992A1 (en) 2005-02-09
UA77532C2 (en) 2006-12-15
PE20040689A1 (es) 2004-10-08
ECSP045410A (es) 2005-01-03
CA2485896A1 (en) 2003-11-27
IL165173A0 (en) 2005-12-18
MXPA04011209A (es) 2005-02-14
RU2326869C2 (ru) 2008-06-20
JP2005533024A (ja) 2005-11-04

Similar Documents

Publication Publication Date Title
ES2195785A1 (es) Nuevos derivados de piridazin-3(2h)-ona.
WO2005049581A8 (en) Pyridazin-3 (2h) -one derivatives and their use as pde4 inhibitors
MY141739A (en) Substituted quinazoline derivatives as inhibitors of aurora kinases
EP1633740A4 (en) CHEMICAL COMPOUNDS
WO2006084017A3 (en) Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
GB0124933D0 (en) Chemical compounds
BG108269A (en) Pyrazolopyrimidines as therapeutic agents
IL181987A0 (en) Diaminotriazole derivatives and pharmaceutical compositions containing the same
JO2311B1 (en) Alkyl inhibitors Ariel phosphodiesterase-4
IL173348A (en) Thienopyridine compounds, pharmaceuticals containing them and their use in the preparation of drugs
RS99203A (en) Pyrrolopyrimidines as protein kinase inhibitors
BG108268A (en) Pyrazolopyrimidines as therapeutic agents
SE0202463D0 (sv) Novel compounds
MXPA03010961A (es) Compuestos de tiazol utiles como inhibidores de proteinas cinasas.
GB0112348D0 (en) Compounds
WO2004100865A3 (en) New benzimidazole derivatives
AP2003002929A0 (en) Pyrrolopyrimidines as protein kinase inhibitors
HK1063185A1 (en) Quinoline derivatives and their use as tyrosine kinase inhibitors
MXPA03009750A (es) Compuestos quimicos.
TNSN05265A1 (en) Composition comprising a pde4 inhibitor and a pde5 inhibitor
GB0308201D0 (en) Novel compounds
WO2002070469A3 (en) Selective pde3b inhibitors and use of the same in therapy
DE50211929D1 (en) Pyrimidinderivate
MXPA04005809A (es) Inhibidores de proteinas quinasas.
IL173629A0 (en) Imidazo(4,5-b) pyridine derivatives and pharmaceutical compositions containing the same

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2195785B1

Country of ref document: ES

FD1A Patent lapsed

Effective date: 20101018